Aidence vs Biofourmis

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Aidence employs 1-50 people, while Biofourmis has 100-500 employees.

Biofourmis has raised more in total funding at $445M, compared to Aidence's $20M — a gap of $425M.

Biofourmis holds the higher Awaira Score at 73/100, compared to Aidence's 45/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 28-point gap that reflects meaningful differences in scale or traction.

Aidence was founded by Jeroen Vendrig in 2016. Biofourmis was founded by Kuldeep Singh in 2015. Visit each company's profile on Awaira for a full founder biography.

Aidence: Aidence develops AI radiology software for lung cancer detection, building CE-marked and FDA-cleared deep learning algorithms that analyse CT scan images to identify and characterise pulmonary nodules requiring clinical follow-up. The Amsterdam company tools assist radiologists in national lung cancer screening programmes and in routine clinical CT reading, providing AI-generated nodule measurements, growth tracking, and malignancy risk scores that reduce reader variability and improve early detection rates.\n\nThe company raised approximately $20 million in venture funding and has deployed its Veye Chest algorithm across multiple European radiology networks and hospital systems participating in national lung cancer screening initiatives. Aidence received CE marking for its software as a medical device and has published clinical validation studies demonstrating performance that is non-inferior to specialist radiologist reads on lung nodule detection tasks.\n\nAidence competes in the AI radiology market alongside Annalise AI, Enlitic, Behold.ai, and Lunit, all of which target chest X-ray and CT reading assistance. The lung cancer screening market has expanded significantly as multiple European countries and the United States have implemented or planned national screening programmes for high-risk smokers, creating a growing workflow automation opportunity for AI lung nodule detection tools. The company was acquired by Coreline Soft, a South Korean medical AI company, as part of a broader consolidation in the AI radiology market. Biofourmis: Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in hospital-at-home programs, enabling earlier clinical intervention and reducing avoidable readmissions for heart failure, oncology, and post-surgical patients.\n\nThe company raised approximately $445 million including a Series D from investors including SoftBank Vision Fund 2, Openspace Ventures, and Mass General Brigham Ventures. Biofourmis has built partnerships with health systems including Brigham and Women Hospital, Guy Hospital, and several major Asian health systems for remote monitoring program deployment, and has entered into pharmaceutical partnerships for using its digital monitoring platform as a clinical trial measurement tool to capture digital endpoints.\n\nBiofourmis competes in the remote patient monitoring and digital therapeutics market against BioIntelliSense, Current Health, and Validic, as well as the monitoring capabilities of established medical device companies including Philips and Masimo that are adding AI analytics to their remote monitoring platforms. The hospital-at-home model, which uses continuous remote monitoring AI to substitute inpatient hospital stays for selected patient populations, represents a significant healthcare cost reduction opportunity that health systems in the US, UK, and Asia are actively piloting.

Biofourmis was founded first in 2015, giving it 1 year of additional market experience. Aidence was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Aidence has approximately 1-50 employees, while Biofourmis has approximately 100-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Aidence and Biofourmis are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.